Understanding What Comes Next
Lutetium-177 (Lu-177) therapy is a form of targeted radionuclide therapy used to treat certain cancers. Lu-177 PSMA therapy targets prostate cancer cells, while Lu-177 DOTATATE therapy targets neuroendocrine tumours. Both work on the same principle: a radioactive atom (Lutetium-177) is attached to a molecule that seeks out and binds to specific receptors on cancer cells, delivering radiation directly to the tumour.
The treatment itself is administered as an intravenous infusion, typically in a nuclear medicine department. But what happens after you leave the hospital? This post covers what to expect during recovery, the precautions you will need to follow, and the follow-up schedule ahead.
The First Few Days: Radiation Precautions
After Lu-177 therapy, your body contains a small amount of radioactivity. The Lutetium-177 is eliminated from your body primarily through urine, with smaller amounts through stool and sweat. Most of the radioactivity is cleared within the first 48 to 72 hours, but precautions are typically recommended for about one week after treatment.
Standard Precautions
Your nuclear medicine team will give you specific written instructions. Common precautions include:
- Distance from others: Maintain a reasonable distance (about 1 to 2 metres) from other people, especially children and pregnant women, for the first few days. You do not need to isolate yourself completely, but prolonged close contact should be limited.
- Sleeping arrangements: Sleep in a separate bed for the first few nights if possible.
- Bathroom hygiene: Flush the toilet twice after use. Sit down to urinate (men included) to minimise contamination. Wash hands thoroughly after using the bathroom.
- Hydration: Drink plenty of fluids to help flush the radioactive material from your body more quickly. This is one of the most important things you can do.
- Laundry: Wash your clothing and bed linen separately for the first week.
- Travel: You may set off radiation detectors at airports for a short period after treatment. Your nuclear medicine centre will provide a letter or card confirming your recent treatment.
These precautions are straightforward and temporary. The radiation levels decrease rapidly, and within a week, most patients can resume normal close contact with family members.
Common Side Effects During Recovery
Lu-177 therapy is generally well-tolerated compared to many other cancer treatments, but side effects do occur. Knowing what to expect helps you distinguish between normal recovery and something that needs medical attention.
Fatigue
Fatigue is the most commonly reported side effect. It may begin within a few days of treatment and can persist for one to several weeks. The severity varies from person to person. Some patients notice only mild tiredness, while others need to significantly reduce their activity levels for a period. Listen to your body and rest when needed. Fatigue tends to improve gradually between treatment cycles.
Nausea
Mild nausea can occur in the first day or two after treatment. Your doctor may prescribe anti-nausea medication to manage this. Eating small, frequent meals rather than large ones can also help.
Dry Mouth
The salivary glands can absorb some of the Lu-177 tracer, potentially causing dry mouth or changes in taste. Sour candies, lemon drops, or chewing gum during and after the infusion can stimulate saliva production and help protect the salivary glands. Your treatment team will advise you on this.
Blood Count Changes
Lu-177 therapy can temporarily affect your bone marrow, leading to decreases in blood cell counts (white blood cells, red blood cells, platelets). This is usually mild and recoverable, but it is monitored closely through regular blood tests. In most cases, counts recover before the next treatment cycle. If counts drop significantly, your doctor may adjust the timing or dose of subsequent cycles.
The Follow-Up Schedule
After each Lu-177 treatment cycle, a structured follow-up schedule begins. This monitoring is essential for assessing treatment response and managing side effects.
Blood Tests
Regular blood tests are the backbone of follow-up monitoring. These include:
- Complete blood count (CBC): Checked every 2 to 4 weeks to monitor bone marrow function.
- Kidney function tests: Lu-177 is partly excreted through the kidneys, so renal function is monitored.
- Liver function tests: Particularly important if there is liver involvement.
- Tumour markers: PSA for prostate cancer patients, or chromogranin A and other markers for neuroendocrine tumour patients. Changes in these markers over time help gauge treatment response.
Imaging
Follow-up imaging is performed to assess the tumour’s response to treatment. The type and timing depend on your specific situation:
- Post-therapy scan: A whole-body scan may be performed 24 to 72 hours after treatment to confirm that the Lu-177 has reached the tumour sites.
- Response assessment scans: PET CT scans (PSMA PET CT for prostate cancer, Ga-68 DOTATATE PET CT for neuroendocrine tumours) are typically performed after 2 to 3 cycles to evaluate treatment response. CT scans may also be used.
Multiple Cycles
Lu-177 therapy is usually given in multiple cycles, typically 4 to 6 cycles spaced 6 to 8 weeks apart. The interval between cycles allows your body to recover, particularly your blood counts.
Before each subsequent cycle, your medical team reviews your blood tests, symptoms, and imaging results to decide whether to proceed. Treatment may be adjusted if side effects are significant or if imaging shows the cancer is not responding. Equally, treatment may be stopped earlier if the response is excellent.
Not every patient completes all planned cycles. The decision is individualised and made collaboratively between you and your treatment team.
Long-Term Monitoring
After completing Lu-177 therapy cycles, follow-up continues on a regular schedule. This typically involves:
- Blood tests and tumour markers every 3 to 6 months
- Imaging scans at intervals determined by your oncologist
- Clinical assessments to monitor symptoms and quality of life
Some patients have sustained responses lasting months or even years after completing treatment. Others may eventually need additional cycles or different treatments. Your doctor will discuss the long-term plan based on your individual response.
Living Well During and After Treatment
Lu-177 therapy does not typically require hospitalisation (beyond the infusion day), and most patients maintain a reasonable quality of life throughout treatment. Staying physically active within your comfort level, eating well, staying hydrated, and maintaining your regular follow-up appointments all contribute to the smoothest possible treatment journey.
If you experience any new or worsening symptoms between appointments, contact your treatment team rather than waiting for the next scheduled visit.
Learn More
For more information about the specific types of Lu-177 therapy and how they work, visit our pages on Lu-177 PSMA therapy and Lu-177 DOTATATE therapy. Your treating doctor is always the right person to discuss your individual treatment plan, expected outcomes, and any concerns you have during recovery.